Your browser doesn't support javascript.
loading
Contemporary Approach to The Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes- Recommendations from The International Consortium for MDS (icMDS).
Aakash, Fnu; Gisriel, Savanah D; Zeidan, Amer M; Bennett, John M; Bejar, Rafael; Bewersdorf, Jan Philipp; Borate, Uma M; Boultwood, Jacqueline; Brunner, Andrew M; Buckstein, Rena; Carraway, Hetty; Churpek, Jane E; Daver, Naval G; DeZern, Amy E; Efficace, Fabio; Fenaux, Pierre; Figueroa, Maria E; Garcia-Manero, Guillero; Gore, Steven D; Greenberg, Peter L; Griffiths, Elizabeth A; Halene, Stephanie; Hourigan, Christopher S; Kim, Tae Kon; Kim, Nina; Komrokji, Rami S; Kutchroo, Vijay; List, Alan F; Little, Richard F; Majeti, Ravindra; Nazha, Aziz; Nimer, Stephen D; Odenike, Olatoyosi; Padron, Eric; Patnaik, Mrinal M; Platzbecker, Uwe; Della Porta, Matteo G; Roboz, Gail J; Sallman, David A; Santini, Valeria; Sanz, Guillermo; Savona, Michael R; Sekeres, Mikkael A; Stahl, Maximilian; Starczynowski, Daniel T; Steensma, David P; Taylor, Justin; Abdel-Wahab, Omer; Wei, Andrew H; Zhuoer, Xie.
Afiliação
  • Aakash F; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gisriel SD; Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.
  • Zeidan AM; Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA.
  • Bennett JM; James P Wilmot Cancer Center and Division of Hematopathology, University of Rochester Medical Center, Rochester, NY, USA.
  • Bejar R; Division of Hematology and Oncology, Moores Cancer Center, UC San Diego, La Jolla, CA, USA.
  • Bewersdorf JP; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Borate UM; Division of Haematology, the Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
  • Boultwood J; Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Brunner AM; Division of Haematology, Massachusetts General Hospital Brigham, Boston, MA, USA.
  • Buckstein R; Department of Medical Oncology/ Hematology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Carraway H; Leukemia Program, Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Churpek JE; Department of Haematology, Oncology, and Palliative Care, Carbone Cancer Center, The University of Wisconsin-Madison, Madison, WI.
  • Daver NG; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • DeZern AE; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA.
  • Efficace F; Italian Group for Adult Hematologic Diseases (GIMEMA), Health Outcomes Research Unit, Rome, Italy.
  • Fenaux P; Service d'hématologie, Hôpital Saint-Louis (Assistance Publique Hôpitaux de Paris) and Université de Paris-Cité, Paris, France.
  • Figueroa ME; Division of Haematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Garcia-Manero G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gore SD; National Cancer Institute, Cancer Therapy Evaluation Program, Rockville, MD, USA.
  • Greenberg PL; Division of Hematology, Department of Medicine, Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Griffiths EA; Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Halene S; Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA.
  • Hourigan CS; Virginia Tech, Fralin Biomedical Research Institute, Cancer Research Center.
  • Kim TK; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Kim N; NCI, NIH, Bethesda, Maryland.
  • Komrokji RS; Malignant Haematology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Kutchroo V; Brigham and Women's Hospital, Boston, MA, USA.
  • List AF; Precision BioSciences, Inc., Durham, NC, USA.
  • Little RF; National Cancer Institute, Cancer Therapy Evaluation Program, Rockville, MD, USA.
  • Majeti R; Division of Hematology, Department of Medicine, Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Nazha A; Department of Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
  • Nimer SD; Division of Haematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Odenike O; Leukemia Program, University of Chicago Medicine and University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.
  • Padron E; Malignant Haematology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Patnaik MM; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
  • Platzbecker U; Department of Haematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany.
  • Della Porta MG; IRCCS Humanitas Research Hospital, Milan, Italy and Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Roboz GJ; Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY, USA.
  • Sallman DA; Malignant Haematology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Santini V; Myelodysplastic syndromes Unit, Department of Experimental and Clinical Medicine, Haematology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy.
  • Sanz G; Health Research Institute La Fe, Valencia, Spain; Hospital Universitario y Politécnico La Fe, Valencia, Spain; CIBERONC, IS Carlos III, Madrid, Spain.
  • Savona MR; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Sekeres MA; Division of Haematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Stahl M; Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Starczynowski DT; Cincinnati Children's Hospital, Cincinnati, OH.
  • Steensma DP; David Steensma LLC, Cambridge, Massachusetts 02139, USA.
  • Taylor J; Division of Haematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Abdel-Wahab O; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Wei AH; Department of Haematology, Royal Melbourne Hospital, Walter and Eliza Hall Institute of Medical Research and University of Melbourne, Victoria, Australia.
  • Zhuoer X; Malignant Haematology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Mod Pathol ; : 100615, 2024 Sep 23.
Article em En | MEDLINE | ID: mdl-39322118
ABSTRACT
Myelodysplastic neoplasms/syndromes (MDS) are a heterogeneous group of biologically distinct entities characterized by variable degrees of ineffective hematopoiesis. Recently, two classification systems (the 5th edition of the WHO Classification and the International Consensus Classification) further sub-characterized MDS into morphologic and genetically defined groups. Accurate diagnosis and subclassification of MDS require a multistep systemic approach. The International Consortium for MDS (icMDS) summarizes a contemporary, practical, and multimodal approach to MDS diagnosis and classification.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Mod Pathol Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Mod Pathol Ano de publicação: 2024 Tipo de documento: Article